Marinus Pharmaceuticals, Inc. MRNS
We take great care to ensure that the data presented and summarized in this overview for MARINUS PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MRNS
Top Purchases
Top Sells
About MRNS
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Insider Transactions at MRNS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 05
2024
|
Scott Braunstein CHAIRMAN AND CEO |
SELL
Open market or private sale
|
Direct |
12,145
-3.91%
|
$12,145
$1.13 P/Share
|
Aug 05
2024
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,828
-6.23%
|
$4,828
$1.13 P/Share
|
Aug 05
2024
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
SELL
Open market or private sale
|
Direct |
3,621
-5.67%
|
$3,621
$1.13 P/Share
|
Aug 05
2024
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,820
-5.36%
|
$3,820
$1.14 P/Share
|
Aug 05
2024
|
Steven Pfanstiel CFO AND COO |
SELL
Open market or private sale
|
Direct |
4,657
-5.52%
|
$4,657
$1.13 P/Share
|
Jun 18
2024
|
Marvin Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.02%
|
-
|
Jun 18
2024
|
Sara Nochur |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.79%
|
-
|
Jun 18
2024
|
Timothy M Mayleben |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+8.62%
|
-
|
Jun 18
2024
|
Sarah B. Noonberg |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.02%
|
-
|
Jun 18
2024
|
Christine Berni Silverstein |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.02%
|
-
|
Jun 18
2024
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+10.71%
|
-
|
Jun 18
2024
|
Steven Pfanstiel CFO AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
12,733
+13.1%
|
-
|
Jun 18
2024
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+12.34%
|
-
|
Jun 18
2024
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+14.6%
|
-
|
Jun 18
2024
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+13.29%
|
-
|
Jun 18
2024
|
Charles Austin |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+15.89%
|
-
|
Jun 18
2024
|
Elan Ezickson |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+15.54%
|
-
|
Jun 18
2024
|
Seth H. Z. Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+15.11%
|
-
|
Mar 27
2024
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+15.46%
|
$200,000
$4.28 P/Share
|
Feb 20
2024
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
SELL
Open market or private sale
|
Direct |
1,894
-3.45%
|
$17,046
$9.57 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 304K shares |
---|---|
Exercise of conversion of derivative security | 50K shares |
Open market or private sale | 50.9K shares |
---|